Claim of ChatGPT Treating Rosie the Dog's Cancer Stirs AI Biotech Debate
An Australian pet owner turned to ChatGPT for guidance on treating his 8‑year‑old Staffordshire bull terrier’s skin cancer, sparking a heated debate about AI’s role in veterinary medicine. The dog, Rosie, was diagnosed with a common mast cell tumor, and the owner claims the AI‑generated suggestions helped extend her life. Veterinarians and biotech experts caution that relying on unverified AI advice could pose safety risks. The episode highlights a growing clash between innovative AI tools and traditional medical oversight.
To Counter China, FDA Chief Wants to Speed New Drug Trial Process
FDA Commissioner Marty Makary said the agency will slash the amount of non‑safety data required to launch new drug trials in the United States. The streamlined approach aims to eliminate redundant paperwork, focusing only on safety‑related information. Makary framed the...
Novo Cuts 400 Jobs in Indiana as Scholar Rock Refiles Drug Linked to the Factory
Novo Nordisk announced it will cut approximately 400 positions at its recently acquired Bloomington, Indiana manufacturing plant. The cuts follow FDA rejections of drug products from three contract companies that used the facility, citing manufacturing deficiencies. The issues stem from...
Amgen, Zai Lab Team up on DLL3; Janux Gets $35M Milestone Payment
Amgen and China‑based Zai Lab have announced a Phase 1b clinical study that combines Amgen’s T‑cell engager Imdelltra with Zai Lab’s experimental antibody‑drug conjugate zocilurtatug pelitecan, targeting the DLL3 protein in aggressive neuroendocrine cancers. The trial will evaluate safety and early...
Paragon Offshoot Korsana to Go Public in Reverse Merger for Alzheimer's Work
Paragon Therapeutics is spinning out its Alzheimer’s-focused unit, Korsana Biosciences, via a reverse merger that will list the company on a U.S. exchange. The deal, championed by Paragon co‑founder Jonathan Violin, merges Korsana with a publicly traded shell, providing immediate...
How a 20-Year Old Asthma Drug Is Boosting Food Allergy Research
A 20‑year‑old asthma medication, Xolair (omalizumab), is now accelerating food‑allergy research, especially for peanut sensitivities. Recent clinical trials combined the drug with oral immunotherapy, cutting severe reaction rates by roughly 70 percent. The FDA has recently cleared the first oral...
IO Biotech Will File for Bankruptcy After Failure of Cancer Vaccine in Key Trial
Danish biotech IO Biotech announced it will file for Chapter 11 bankruptcy after its lead cancer vaccine failed to demonstrate efficacy in a pivotal trial. The vaccine, designed to treat aggressive solid tumors, showed no statistically significant benefit, prompting the...
Oric to Advance Prostate Cancer Drug to Phase 3, but Combo Choice Raises Doubts
Oric Pharmaceuticals announced that its PRC2 inhibitor will move into a registrational Phase 3 trial for prostate cancer after reporting encouraging safety and disease‑control signals in a Phase 1b study. The company plans to evaluate the drug both as a...
Pharma Goes on $25.5B, Eight-Day Acquisition Spree
Pharmaceutical companies launched an eight‑day acquisition blitz, with six firms announcing deals worth about $25.5 billion. Two of those transactions involve upfront payments exceeding $5 billion each, underscoring the aggressive pace. The deals focus on securing biotech pipelines and specialty drug assets...
Novo Nordisk Launches Subscription Program for Wegovy Drugs
Novo Nordisk introduced a subscription service for its obesity treatment Wegovy, allowing cash‑pay patients to lock in three‑month, six‑month or twelve‑month supplies. The model promises lower out‑of‑pocket costs compared with traditional pay‑per‑dose purchases. By bundling shots and oral pills, Novo...
PepGen’s Muscle Disease Program Posts Poor Mid-Stage Results as One Patient's Data Get Markedly Worse
PepGen reported that its Phase 2 trial of an oligonucleotide therapy for a rare genetic nerve‑muscle disorder failed to meet its primary efficacy endpoints. The data showed no statistically significant improvement in muscle strength across the cohort, and one participant experienced...
ViiV R&D Head Kimberly Smith Heads to Retirement After Three Decades in HIV Care
Kimberly Smith, ViiV Healthcare’s Chief Scientific Officer, is retiring after more than three decades in HIV care, including 13 years leading the company’s R&D division. Smith’s tenure saw the launch of several next‑generation antiretroviral therapies and the expansion of ViiV’s...
Eli Lilly to Buy Centessa for $6.3B to Get Sleep Disorder Drug
Eli Lilly announced a $6.3 billion acquisition of Centessa Pharmaceuticals, marking its largest deal in years. The purchase secures Centessa’s orexin‑based insomnia candidate and a pipeline of early‑stage neurological programs. Lilly is channeling cash generated by its GLP‑1 blockbuster drugs into the...
First Clinical Trial of tRNA Therapy Will Start Soon
Alltrna, a biotech startup focused on transfer RNA (tRNA) therapeutics, has secured regulatory clearance to launch its first human clinical trial. The trial will evaluate a novel tRNA‑based drug designed to correct protein synthesis errors that underlie a range of...
Enveda's First Clinical Readout Shows Strong Eczema Results
Enveda Biosciences released its first clinical readout for an investigational atopic dermatitis therapy, showing efficacy comparable to AbbVie's Dupixent. The Phase 1 trial met its primary endpoints, demonstrating significant skin clearance and a safety profile similar to existing biologics. The...
#ACC26: Merck Touts Comparator Data for Oral Cholesterol Drug
Merck reported that its experimental oral PCSK9 inhibitor, enlici‑tide, outperformed a range of commonly prescribed cholesterol‑lowering medicines in a head‑to‑head comparator trial. The data bring the drug a step closer to becoming the first oral PCSK9 therapy on the market....
#AAD26 Roundup: Takeda, Alumis, Priovant and Incyte Take the Stage
At the American Academy of Dermatology (AAD) meeting in Denver, Takeda, Alumis, Priovant and Incyte each unveiled late‑stage dermatology data, ranging from novel biologics to targeted small molecules. Sanofi and Biogen also presented, highlighting mixed results in eczema and lupus...
Kailera Plans IPO for Phase 3 Obesity Drug From Hengrui
Kailera Therapeutics, one of biotech’s best‑funded startups, announced plans to go public to finance the Phase 3 trial of its obesity drug co‑developed with China’s Hengrui. The IPO aims to raise capital that will position the company against heavyweight rivals such...
#ACC26: Merck Leans Toward Lower Winrevair Dose in Phase 3 Trial for Rare Form of Heart Failure
Merck announced that its experimental drug Winrevair will move into a pivotal Phase 3 trial for a rare form of heart failure, focusing on the lowest dose tested in Phase 2. The Phase 2 data showed a "pretty profound" efficacy signal at that...
#AAD26: Biogen Declares Phase 2 Lupus Success for Anti-BDCA2 Antibody
Biogen announced positive Phase 2 results for litifilimab, its anti‑BDCA2 antibody targeting systemic lupus erythematosus. After 24 weeks, 14.7% of patients achieved complete clearance of skin lesions, meeting the trial’s primary endpoint. The data suggest the drug could become a...
#AAD26: Tanabe’s Phase 3 Win for Drug Targeting Rare Diseases that Cause Pain upon Light Exposure
Tanabe Pharma announced that its oral investigational drug achieved positive results in a pivotal Phase 3 trial for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), two ultra‑rare phototoxic disorders. The study met its primary endpoint of reducing light‑induced pain episodes and...
CHMP Recommends Subcutaneous Form of Sanofi's Sarclisa and Four New Drugs
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on five products: a subcutaneous formulation of Sanofi’s multiple‑myeloma therapy Sarclisa and four entirely new drugs pending approval. The subcutaneous version aims to simplify...
AnaptysBio Spins Out Biotech Operations; Affibody's Data in Hidradenitis Suppurativa
AnaptysBio announced the spin‑out of its biotech operations into a newly formed independent public company, First Tracks Biotherapeutics. The separation isolates AnaptysBio’s early‑stage pipeline, giving First Tracks a focused platform to advance its candidates. The announcement also highlighted promising data...
FDA Approves Novo Nordisk's Once-Weekly Insulin
The U.S. Food and Drug Administration has approved Novo Nordisk’s once‑weekly insulin, the first longer‑acting basal therapy for type‑2 diabetes in the United States. The product, insulin icodec, demonstrated non‑inferior HbA1c reduction and comparable safety to daily basal insulins in...
AstraZeneca’s in Vivo CAR-T Led to Early Responses, but One Death in China Trial
AstraZeneca’s in‑vivo CAR‑T platform, acquired last year, has entered a Phase I/II trial in China for relapsed/refractory multiple myeloma. Early data show a 33% overall response rate with several partial remissions, but the study also reported one death due to severe...
Novartis to Spend up to $2B on Excellergy and Its Next-Gen Xolair Candidate
Novartis announced it will pay up to $2 billion upfront to acquire Excellergy Inc., securing the biotech’s next‑generation anti‑IgE candidate. The move comes as Xolair, Novartis’ blockbuster allergy drug, prepares for imminent biosimilar competition that could erode its market share. By...
Recursion Appoints Former Exelixis CMO; More Executive Moves at Incyte
Recursion Therapeutics announced the appointment of Vicki Goodman as its new chief medical officer, bringing her extensive oncology and drug‑development experience from a decade as CMO at Exelixis. Goodman will oversee clinical strategy for Recursion’s AI‑driven pipeline, aiming to accelerate...
AstraZeneca’s COPD Antibody Gets Phase 3 Wins in Broader-than-Expected Population
AstraZeneca announced that its investigational COPD antibody achieved positive results in two Phase 3 trials, marking a turnaround after a previous mid‑stage failure. The studies demonstrated statistically significant improvements in lung function and exacerbation rates across a broader patient population...
Top HHS Official Makes Impassioned Pitch to Take on China Biotech
Senior HHS official and Medicare administrator Chris Klomp warned that competition with China’s rapidly advancing biotech sector is “a war,” signaling heightened urgency in U.S. policy circles. He highlighted gaps in domestic research funding, manufacturing capacity, and talent pipelines that...
Biopharma Industry Pushes Back on FDA's 'America First' User Fee Proposals
The FDA’s upcoming user‑fee framework, dubbed "America First," seeks to tighten eligibility for the small‑business waiver, limiting it to U.S.‑based applicants. Industry groups argue the change politicizes fee policy and could disadvantage foreign‑owned biotech firms that rely on the waiver...
Recordati Says It's Received a $12B+ Takeover Bid
Italian pharmaceutical group Recordati announced it has received a takeover proposal valued at more than $12 billion. The bid, disclosed in a press release, comes from an undisclosed consortium of investors. Recordati, known for specialty drugs and generics, said the offer...
Kodiak’s Phase 3 Eye Drug Success; Innate Discontinues Anti-CD20 Program
Kodiak Sciences announced that its experimental eye drug Zenkuda (tarcocimab tedromer) achieved positive topline results in the GLow2 Phase 3 trial for diabetic retinopathy, outperforming sham treatment. The study met its primary endpoint, delivering a statistically significant gain in visual acuity...
Post-Hoc: It’s Time to Make ACIP Serious Again
The Advisory Committee on Immunization Practices (ACIP) is under renewed scrutiny after former member Robert Malone suggested on social media that the committee could be disbanded. Critics argue that political interference has eroded the panel’s scientific credibility, prompting calls for structural...
Oral Peptides Biotech Pinnacle Medicines Gets $89M From US, China Investors
Pinnacle Medicines, a two‑year‑old biotech focused on oral peptide therapeutics, secured $89 million from a mix of U.S. and Chinese investors. The financing will fund its platform that converts injectable peptides into pill form, building on the recent success of Novo...
More Changes Ahead for Takeda with New CEO Set to Take Reins
Takeda Pharmaceutical announced that Julie Kim will assume the role of chief executive, continuing the company’s multi‑year restructuring agenda. The board approved a new phase of the transformation, emphasizing the rollout of upcoming product launches and accelerating late‑stage pipeline development....
How Seaport Is Hedging Against Failure in Phase 2b Depression Study
Seaport Therapeutics is embedding a fail‑safe mechanism into its Phase 2b trial of SPT‑300, an experimental therapy for major depressive disorder. The study will enroll roughly 300 patients at multiple U.S. sites and uses an adaptive design that can halt...
Beam Looks to Accelerated Approval for AATD Base Editing After Promising Update
Beam Therapeutics announced encouraging Phase 1/2 data for its base‑editing therapy targeting alpha‑1 antitrypsin deficiency (AATD). The trial demonstrated a 30% reduction in the disease‑causing SERPINA1 mutation and a 45% rise in functional protein levels, while confirming a clean safety profile....
Boehringer Ingelheim Plans for Dealmaking and R&D Spending Amid US Price Pressure
Boehringer Ingelheim announced it will maintain its high‑level R&D spending while exploring dealmaking opportunities in China to counteract mounting U.S. drug‑price pressure. The company is prioritising an obesity‑focused pipeline, betting on the fast‑growing weight‑loss market to sustain revenue. By keeping...
Novo Reports More Triple-G Data From China; Grifols Plots IPO for Biopharma Unit
Novo Nordisk announced that its triple‑agonist candidate UBT251 achieved a mean HbA1c reduction of up to 2.16% after 24 weeks in a phase‑2 study of Chinese patients with type‑2 diabetes. The trial, involving roughly 200 participants, underscores the drug’s potential...
Microneedle Vaccine Patch Company Raises $50M for Pivot to GLP-1 Delivery
Terrestrial Bio, the microneedle vaccine patch pioneer originally founded as Vaxess Technologies, announced a $50 million Series B financing round to shift its focus from vaccines to GLP‑1 peptide delivery. The capital, led by a consortium of biotech investors, will fund clinical...
Maze Meets Own Expectations in Phase 2 Kidney Disease Trial in the Same Arena as Vertex
Maze Therapeutics reported that its Phase 2 trial of the genetic kidney disease candidate MZ‑001 achieved its primary efficacy and safety goals, showing a roughly 30% slowdown in eGFR decline versus placebo. The double‑blind study enrolled 150 patients with autosomal dominant...
Ocugen Heads to Phase 3 with Gene Therapy for Geographic Atrophy
Ocugen announced that its investigational gene therapy for geographic atrophy, a leading cause of vision loss in age‑related macular degeneration, will move into a Phase 3 clinical trial. The company reported mixed Phase 2 results, showing a favorable safety profile but inconsistent...
Lessons From the Last Health Tech Revolution
Farzad Mostashari, former US national coordinator for health IT, reflects on the chaotic rollout of electronic health records (EHR) and draws parallels to today’s AI hype in healthcare. He argues that the last health‑tech revolution exposed systemic flaws—interoperability gaps, clinician...
FDA Warns ImmunityBio over Misleading Podcast with Patrick Soon-Shiong
The U.S. Food and Drug Administration issued a warning to ImmunityBio after a television ad and a podcast featuring billionaire biotech entrepreneur Patrick Soon‑Shiong suggested that the company’s bladder‑cancer drug Anktiva could cure or prevent all cancers. The FDA said...
Karyopharm’s Mixed Myelofibrosis Data; Rezolute to Seek FDA Approval Despite Trial Failure
Karyopharm reported mixed results from its Phase 3 SENTRY trial of selinexor in myelofibrosis, achieving a statistically significant reduction in spleen volume but raising safety concerns. The data fell short of expectations for overall survival benefit. Meanwhile, Rezolute announced it will...
Q&A: Controversial Embryo Editing Entrepreneur Cathy Tie on Her New Startup
Cathy Tie, the founder of Origin Genomics, announced the shutdown of her previous embryo‑editing venture and the launch of a new startup focused on pre‑implantation genetic modification. The new company, dubbed EmbryoX, has secured $55 million in Series A funding led by...
XO Health to Expand Its Alternative Health Plan Nationwide
XO Health, a startup that provides an alternative health plan, announced a nationwide rollout targeting self‑insured employers and plan administrators. The company will extend its episode‑based pricing model, which bundles all services for a specific medical episode into a single,...
Triangle Health Raises $4M as People Turn to AI to Understand Their Health
Triangle Health announced a $4 million Series A raise to expand its AI‑driven platform that translates personal health records into actionable treatment insights. The startup’s technology ingests uploaded medical data, generates comparative treatment options, and produces patient‑friendly summaries. Funding comes from a...
Biotech Investors Set to Meet with Key Congressional Panel
A bipartisan congressional commission focused on maintaining U.S. leadership in biotechnology will host a meeting with leading biotech investors next week. The investors, representing venture capital firms and industry funds, aim to discuss policy gaps, funding mechanisms, and regulatory hurdles....
Apnimed Set to Exit Sleep Disorder Joint Venture with Shionogi for $100M Upfront
Japanese pharmaceutical company Shionogi is buying out Apnimed’s 50% stake in their sleep‑disorder joint venture for an upfront payment of $100 million. The acquisition gives Shionogi full control over the partnership’s pipeline, which focuses on treatments for conditions such as obstructive...
